NCYT Stock Chart & Stats
36.95 p
-0.45 p(-1.22%)
At close: 4:00 PM EDT
36.95 p
-0.45 p(-1.22%)
Day’s Range― - ―
52-Week Range26.60 p - 86.00 p
Previous CloseN/A
Volume4.79K
Average Volume (3M)52.55K
Market Cap
£32.13M
Enterprise Value17.64 p
Total Cash (Recent Filing)£19.14M
Total Debt (Recent Filing)£10.44M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding72,588,090
10 Day Avg. Volume18,300
30 Day Avg. Volume52,550
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)1.35
P/FCF Ratio-3.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-12.27
Revenue Forecast (FY)£2.59B
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 63% blended gross margin, supported by >80% margins on Primerdesign PCR/RUO sales, provides durable unit economics. High product-level margins give the company room to invest in sales/R&D, absorb pricing pressure in low-cost markets, and scale toward EBITDA profitability as volumes rise.
IVDR Regulatory ApprovalIVDR accreditation creates a structural regulatory barrier that can limit new entrants and reduce competitor activity in Europe. This certification supports longer product life, reimbursement acceptance and customer retention, strengthening the company’s competitive moat over the next 12–24 months.
Strategic Acquisition (Southern Cross)The Southern Cross deal is earnings‑accretive and diversifies revenue into a fast-growing, complementary diagnostics channel. With >GBP6m revenue and integration mostly complete, the acquisition adds recurring sales, distribution scale and cross-sell opportunities that can sustainably bolster top-line growth.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow raises financing risk and constrains strategic optionality. Continued cash consumption forces reliance on external funding, limits capacity to invest organically, and makes meeting growth and EBITDA targets contingent on tighter execution or new capital.
Structural Operating LossesSustained operating losses indicate the current revenue base does not yet cover the cost structure. This undermines returns on shareholder capital, shrinks equity, and elevates execution risk: achieving durable profitability requires consistent revenue scaling and further OpEx discipline.
Large Impairments & Exceptional ChargesMaterial non‑cash impairments and exceptional charges reflect previous overvaluation or underperformance of assets, weakening the balance sheet and reducing intangible value. Such writedowns can constrain future borrowing, signal integration challenges, and create volatility in reported earnings.
Novacyt News
NCYT FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest share price was 26.60 p and its highest was 86.00 p in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is £32.13M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 37 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -0.23 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -0.23 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.635%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in GB:NCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
NCYT Company Deck
NCYT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all GB:NCYT earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―